Randy D. Gascoyne, MD, FRCPC
Department of Pathology, Division of Hematopathology, British Columbia Cancer Agency/BC Cancer Research Centre and the University of British Columbia, Vancouver, BC, Canada
Randy Gascoyne is Clinical Professor of Pathology at the British Columbia Cancer Agency (BCCA), Vancouver, Canada. He has been a practising haematopathologist at the BCCA for 28 years and a distinguished scientist at the BC Cancer Research Centre, where he was Department Head of Lymphoid Cancer Research.
Areas in which Professor Gascoyne has special interest include the molecular biology and pathogenesis of lymphomas, pathobiology of Hodgkin lymphoma, molecular mechanisms underlying altered gene expression in lymphoma, gene expression profiling, high-throughput genomics studies of lymphoid cancers, the role of the microenvironment in lymphoid cancers, mechanisms of acquired immune privilege in lymphoid cancers, and biomarker development in lymphoid cancers.
With 476 peer-reviewed articles, 31 book chapters, and 476 abstracts, Professor Gascoyne is Canada’s most-published pathologist. He serves on numerous advisory boards related to lymphoma and editorial boards of journals such as Advances in Anatomic Pathology and Journal of Clinical Oncology, and is a member of several medical societies, including the American Society of Hematology (ASH), Canadian Association of Pathologists (CAP), and European Association of Haematopathology (EAHP). Professor Gascoyne is a regularly invited speaker at national and international meetings. A prominent research career has resulted in a current h-index of 91. He has received many awards, including a Doctor Honoris Causa from Paul Sabatier University (Toulouse, France) in 2011 and the Dr. John Ultmann Award at the 15th annual meeting of Lymphoma & Myeloma 2015 for contributions to lymphoma research. In 2014 and 2015, he made the list of the top 1% Most Influential Scientific Minds in the World, based on citations over a 12-year period. In 2016, he was awarded the Aubrey J. Tingle award from the Michael Smith Foundation for Health Research.